Medicamen Organics Share Price | Medicamen Organics Stock Screener
MEDIORG
Pharmaceuticals
Track Medicamen Organics share price live with TickJournal's free stock screener.
Check Medicamen Organics 52-week for the annual price range and momentum.
Use the Medicamen Organics stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Medicamen Organics Market Cap
₹31.59 Cr.
MEDIORG P/E Ratio (TTM)
-
Medicamen Organics P/B Ratio
1.04
EPS (TTM)
₹3.67
Dividend Yield
-
Debt to Equity
0.55
MEDIORG 52 Week High
-
Medicamen Organics 52 Week Low
-
Operating Margin
-
Profit Margin
-
MEDIORG Revenue (TTM)
-
EBITDA
-
Net Income
-
Total Assets
₹59.00
Total Equity
₹31.00
Medicamen Organics Share Price Chart
Screen Medicamen Organics share price with an interactive chart. Analyse MEDIORG price trends and volatility across different timeframes.
Medicamen Organics Company Profile - Fundamental Screener
Screen Medicamen Organics company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for MEDIORG shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE0PE401018
Medicamen Organics Balance Sheet Screener
Screen MEDIORG balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2025 | 2024 |
|---|---|---|
| Assets | ||
| Total Assets | 59 | 38 |
| Current Assets | 45 | 27 |
| Fixed Assets | 10 | 10 |
| Liabilities | ||
| Total Liabilities | 0 | 0 |
| Current Liabilities | 2 | 2 |
| Non-Current Liabilities | 0 | 0 |
| Shareholders' Equity | ||
| Total Equity | 31 | 15 |
| Share Capital | 12 | 9 |
| Reserves & Surplus | 18 | 7 |
Medicamen Organics Income Statement Screener - Profit & Revenue Analysis
Screen Medicamen Organics income statement and profit fundamentals.
Analyze MEDIORG quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Medicamen Organics share price evaluation.
| Item | None-None | 2025-March | 2024-March |
|---|---|---|---|
| Revenue | 0 | 38 | 25 |
| Expenses | 0 | 32 | 21 |
| EBITDA | 0 | 7 | 5 |
| Operating Profit % | 0.00% | 17.00% | 19.00% |
| Depreciation | 0 | 1 | 1 |
| Interest | 0 | 1 | 1 |
| Profit Before Tax | 0 | 5 | 4 |
| Tax | 0 | 1 | 2 |
| Net Profit | 0 | 4 | 3 |
| EPS | 0.00 | 3.67 | 3.47 |
Medicamen Organics Cash Flow Screener - Liquidity Fundamentals
Screen MEDIORG cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March |
|---|---|---|
| Operating Activities | -5 | -4 |
| Investing Activities | -2 | 0 |
| Financing Activities | 11 | 4 |
| Net Cash Flow | 4 | 0 |
Medicamen Organics Shareholding Pattern Screener
See Medicamen Organics shareholding pattern with promoter, FII, and DII holdings.
Check Medicamen Organics promoter holding and ownership changes for MEDIORG on TickJournal.
| Item | 2026-Mar | 2026-Jan | 2025-Sept | 2025-Mar | 2024-Sept | 2024-Jun | 2024-Feb |
|---|---|---|---|---|---|---|---|
| Promoter Holding | 59.73% | 61.27% | 59.73% | 59.73% | 59.69% | 59.69% | 81.21% |
| FII Holding | 0.07% | 0.07% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 1.64% | 3.55% | 0.00% | 0.10% | 0.07% | 0.27% | 0.00% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 30.79% | 28.75% | 30.58% | 28.79% | 28.27% | 13.85% | 0.00% |
| Other Holding | 7.78% | 6.36% | 9.69% | 11.38% | 11.97% | 26.19% | 18.79% |
| Shareholder Count | 540 | 515 | 507 | 460 | 379 | 34 | 34 |
Medicamen Organics Share Dividend Screener - Share Yield Analysis
Check Medicamen Organics dividend history with payout and yield data.
View Medicamen Organics dividend details including ex-dates and amounts for MEDIORG stock.
Medicamen Organics Stock Index Membership
See which indices include Medicamen Organics stock.
Check MEDIORG index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Medicamen Organics Market Events Screener - Corporate Actions
Get Medicamen Organics corporate actions including splits, bonuses, and buybacks.
Check Medicamen Organics stock events that may affect MEDIORG share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | -5.45% | ||
| 2026-04-09 | 2026-04-09 | Extraordinary General Meeting | NA | 27.27% |
| 2025-11-14 | 2025-11-14 | Quarterly Result Announcement | NA | -6.98% |
| 2025-05-29 | 2025-05-29 | Quarterly Result Announcement | NA | 15.46% |
| 2024-11-14 | 2024-11-14 | Quarterly Result Announcement | NA | 1.32% |
Medicamen Organics Competitors Screener - Peer Comparison
Screen MEDIORG competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 457,265 | 41.18 | 54,729 | 9.71% | 10,980 | 64.89 |
| Divis Laboratories | 181,448 | 72.40 | 9,712 | 18.67% | 2,191 | 64.06 |
| Torrent Pharmaceuticals | 148,703 | 65.64 | 11,539 | 6.99% | 1,911 | 58.52 |
| Cipla | 115,206 | 29.94 | 27,712 | -2.46% | 3,783 | 69.78 |
| Dr Reddys Laboratories | 111,108 | 26.84 | 33,593 | -0.44% | 3,998 | 59.87 |
| Mankind Pharma | 103,024 | 57.32 | 12,744 | 20.90% | 2,007 | 73.37 |
| Lupin | 102,944 | 19.41 | 27,488 | 19.98% | 5,345 | 46.11 |
| Zydus Life Science | 99,728 | 20.25 | 23,511 | 18.55% | 4,615 | 69.47 |
| Aurobindo Pharma | 87,149 | 25.19 | 32,346 | 9.43% | 3,484 | 73.83 |
| Laurus Labs | 71,655 | 80.32 | 6,813 | 21.03% | 884 | 80.26 |
Medicamen Organics Company Announcements - News Screener
Screen MEDIORG latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.